Johnson & Johnson Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Johnson & Johnson de 5.1% y 3.3% por año respectivamente. Se prevé que el BPA crezca en un 6.5% al año. Se espera que la rentabilidad financiera sea de 32.7% en 3 años.

Información clave

5.1%

Tasa de crecimiento de los beneficios

6.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	3.2%
Rentabilidad financiera futura	32.7%
Cobertura de analistas	Good
Última actualización	01 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Apr 11

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Jan 25

Previsiones de crecimiento de beneficios e ingresos

NYSE:JNJ - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	93,807	24,306	23,729	N/A	19
12/31/2025	90,771	22,970	22,965	N/A	22
12/31/2024	88,374	22,025	23,201	N/A	22
3/31/2024	85,648	19,171	N/A	N/A	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	98,656	13,992	15,737	20,278	N/A
7/2/2023	97,301	13,993	14,547	19,073	N/A
4/2/2023	96,263	12,724	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	18,377	22,007	N/A
3/31/2019	81,593	14,679	18,470	22,138	N/A
12/30/2018	81,581	15,297	18,531	22,201	N/A
9/30/2018	81,382	1,542	18,470	22,062	N/A
7/1/2018	80,684	1,372	18,493	22,056	N/A
4/1/2018	78,693	1,245	18,372	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A
9/28/2014	74,232	17,321	N/A	18,245	N/A
6/29/2014	73,340	15,554	N/A	19,538	N/A
3/30/2014	71,722	15,061	N/A	19,060	N/A
12/29/2013	71,312	13,831	N/A	17,414	N/A
9/29/2013	70,515	12,879	N/A	16,651	N/A
6/30/2013	69,992	12,865	N/A	15,684	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (5.1% al año) de JNJ es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (5.1% al año) de JNJ crezcan menos que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de JNJ crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (3.3% al año) de JNJ crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.3% al año) de JNJ crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de JNJ sea alta dentro de 3 años (32.7%)

Johnson & Johnson Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

First quarter dividend increased to US$1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Johnson & Johnson Announces New Analysis of Data from the PionEER AF-PCI Clinical Trial Demonstrating XARELTO®? (rivaroxaban)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson to Showcase its Latest Innovations to Combat Cardiovascular Disease at ACC.24

With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Recommends Carvykti®? (Ciltacabtagene Autoleucel) for the Early Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Insider recently sold US$1.4m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Johnson & Johnson Announces the First Data from FRONTIER 2, the Long-Term Extension of the Phase 2b FONTIER 1 Clinical Trial Evaluating JNJ-2113

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders.

Johnson & Johnson: A Clean Bill Of Health

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves the Supplemental Biologics License Application for TECVAYLI®?

Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?

Insider notifies of intention to sell stock

Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

Upcoming dividend of US$1.19 per share at 3.0% yield

Johnson & Johnson Announces Publication in the New England Journal of Medicine of the Phase 2b FRONTIER 1 Trial Results for JNJ-2113

Johnson & Johnson Reports Positive Topline Results for Nipocalimab from Phase 3 Pivotal Study in Generalized Myasthenia Gravis and Phase 2 Study in Sjögren's Disease

Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seek Approval of DARZALEX FASPRO

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Johnson & Johnson Announces New Clinical and Real-World Evidence Data Will Be Featured in 18 Abstracts at This Year's ASCO GU Symposium

Full year 2023 earnings: EPS misses analyst expectations

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento